prostate

Treatment resistance caused by cancer cell plasticity constitutes a major challenge in the treatment of prostate cancer. Published in Nucleic Acids Research, a recent study from the University of Eastern Finland Institute of Biomedicine suggests that the SIX2 protein may be a possible factor underlying increased plasticity of prostate cancer cells and treatment resistance. Prostate cancer is the most common cancer in men and the second most common cause of cancer mortality in Western countries. Prostate cancer growth is promoted by androgens and can be treated with androgen receptor inhibition therapies, especially as regards aggressive or advanced prostate cancer. However,

Chromatin openness sheds new light on prostate cancer plasticity as seen on The Hippocratic Post.